drugset
drugset / Trial / NCT05250245

Tolterodine Relieves Overactive Bladder Symptoms in Women With Moderate-to-severe Obstructive Sleep Apnea Syndrome

NCT05250245 ↗

Phase 4 Completed 60 enrolled Yuzuncu Yil University
RandomizedParallel-groupOpen-labelTreatment

Summary

In this study, we aim to determine whether combined tolterodine and CPAP therapy is a more effective treatment for patients with OSAS than CPAP treatment only.

Timeline

Start
2020-06-01
Primary completion
2021-12-30
Completion
2022-01-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tolterodine Small molecule 4 mg —

Indications

obstructive sleep apnea syndrome overactive bladder